Dietary supplement maker Elysium Health Inc said it raised $20 million in funding from a group of investors led by venture capital firm General Catalyst.
Elysium, which claims its product repairs cells damaged by natural health decline, was founded in 2015 and counts seven Nobel laureates in its advisory board.
The product, called Basis, enhances levels of an enzyme known as NAD+, which is critical for cellular function. As we age, NAD+ levels naturally decline.
Studies have shown that if you restore NAD+ levels in an old animal, you can help it live longer, Chief Scientist and founder Leonard Guarente, who also leads the Science of Aging Lab at the Massachusetts Institute of Technology, told Reuters.
On Tuesday, Elysium released the results of an eight-week study testing Basis in 120 healthy older volunteers. Data showed…